Loading...
XNAS
ABOS
Market cap90mUSD
Jul 18, Last price  
1.50USD
1D
1.35%
1Q
66.52%
IPO
-92.60%
Name

Acumen Pharmaceuticals Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
8.37%
Rev. gr., 5y
%
Revenues
0k
1,697,0001,436,0000000
Net income
-102m
L+95.39%
-7,862,000-7,324,000-181,679,000-40,475,000-52,371,000-102,329,000
CFO
-86m
L+100.20%
-6,818,000-7,450,000-17,961,000-35,153,000-43,064,000-86,215,000
Earnings
Aug 11, 2025

Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
IPO date
Jul 01, 2021
Employees
39
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
114,017
103,456
45,406
Unusual Expense (Income)
NOPBT
(114,017)
(103,456)
(45,406)
NOPBT Margin
Operating Taxes
(2,381)
Tax Rate
NOPAT
(114,017)
(103,456)
(43,025)
Net income
(102,329)
95.39%
(52,371)
29.39%
(40,475)
-77.72%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,897
121,904
3,907
BB yield
-7.65%
-65.31%
-1.78%
Debt
Debt current
133
1,732
105
Long-term debt
28,882
28,771
105
Deferred revenue
Other long-term liabilities
970
2,560
Net debt
(142,542)
(275,572)
(193,232)
Cash flow
Cash from operating activities
(86,215)
(43,064)
(35,153)
CAPEX
(16)
(21)
(161)
Cash from investing activities
48,027
(171,671)
39,185
Cash from financing activities
6,928
151,753
3,907
FCF
(113,853)
(103,689)
(43,259)
Balance
Cash
171,557
243,522
177,605
Long term investments
62,553
15,837
Excess cash
171,557
306,075
193,442
Stockholders' equity
(325,169)
(222,480)
(171,174)
Invested Capital
536,687
521,366
360,054
ROIC
ROCE
EV
Common stock shares outstanding
60,013
48,609
40,602
Price
1.72
-55.21%
3.84
-28.89%
5.40
-20.12%
Market cap
103,223
-44.70%
186,660
-14.86%
219,250
-19.86%
EV
(39,319)
(88,912)
26,018
EBITDA
(113,839)
(103,272)
(45,237)
EV/EBITDA
0.35
0.86
Interest
4,068
2,381
Interest/NOPBT